(Q27853207)

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

MMP-1 expression has an independent prognostic value in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in libya

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Validation of UBE2C protein as a prognostic marker in node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Impact of sentinel node tumor burden on outcome of invasive breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Benefit from anthracyclines in relation to biological profiles in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

The potential utility of geminin as a predictive biomarker in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective study in Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

An international Ki67 reproducibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

An international study to increase concordance in Ki67 scoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3559-0

10.1007/S10549-015-3559-0

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1816931

1049793786

0 references

Fatcat ID

release_yzk32fzq6vfftkexmhfuy7kdpm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yzk32fzq6vfftkexmhfuy7kdpm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1816931

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference